Welcome to the all-new Vetlearn

  • Vetlearn is becoming part of NAVC VetFolio.
    Starting in January 2015, Compendium and
    Veterinary Technician articles will be available on
    NAVC VetFolio. VetFolio subscribers will have
    access to not only the journals, but also:
  • Over 500 hours of CE
  • Community forums to discuss tough cases
    and networking with your peers
  • Three years of select NAVC Conference
  • Free webinars for the entire healthcare team

To access Vetlearn, you must first sign in or register.


  Sign up now for:
Become a Member

Reference Desk April 2012

Pfizer, Humane Association Studying Benefits of Animal-Assisted Therapy for Children With Cancer

    Literature review and site interviews mark study's launch

    MADISON, New Jersey, April 12, 2012—Pfizer Animal Health and the American Humane Association (AHA) jointly announced completion of the first round of an innovative research study on the benefits of animal-assisted therapy (AAT) on pediatric cancer patients and their families.

    For years, doctors, veterinarians, and other caregivers have shared experiences about the healing power that animal-assisted therapy offers children with cancer. However, little hard evidence exists as to whether these claims can be substantiated, under what conditions AAT is most effective, and how, if proven useful, it may best be incorporated into treatment.

    The research study, “Canines and Childhood Cancer: Examining the Effects of Therapy Dogs with Childhood Cancer Patients and their Families,” is a multiyear effort taking place in hospital settings across the U.S. that will examine the specific medical, behavioral, and mental health benefits AAT may have for children with cancer and their families. A comprehensive literature review has been completed as a first step, and may be downloaded at: www.CaninesAndChildhoodCancer.org.

    “The literature review was conducted to inform the research plan and design for the remainder of the effectiveness study and to provide a resource to help understand the current status of human-animal interaction research within this domain,” said Michael McFarland, DVM, DABVP, Group Director, Veterinary Operations, Companion Animals, U.S. Pfizer Animal Health.

    In addition to the literature review, focus groups and interviews were conducted with hospital staff, family caregivers, and AAT handlers to glean vital information regarding childhood cancer epidemiology and treatment, the well-being of patients and families who are affected by childhood cancer, the applications of AAT for various populations in need, the state of AAT effectiveness research, and the considerations that need to be made when incorporating therapy animals into clinical settings.

    Findings from the literature review, focus groups, and interviews will help guide the design of the overall study. Preliminary findings showed that no standard protocol for an AAT session (i.e., length, number and type of participants in each session, session activities, or talking points) seemed to exist at any of the research hospital sites; each animal-handler team went about its work somewhat differently. This finding underlines the need for this study to develop AAT treatment fidelity across sites in order to conduct the type of rigorous research needed in the human-animal interaction field.

    The information gathered during this initial phase will serve to inform a scientific study design in order to conduct a pilot trial with three to five pediatric oncology sites across the country. Upon the conclusion of the pilot trial, researchers anticipate the launch of a full clinical trial across multiple sites for 12-18 months. During this time, certified therapy dogs and their handlers will conduct regular AAT sessions with pediatric oncology patients and their families, which will be evaluated by a range of biological, psychological, and social measures.

    “Now we begin the important work of validating and quantifying something that we have observed and felt for years through our own experiences—that interaction with animals can provide beneficial effects for people in need of comfort, encouragement and healing,” said Robin R. Ganzert, Ph.D., AHA President and Chief Executive Officer.

    Results from the study will be widely disseminated through professional conferences and peer-reviewed journals in a diverse range of disciplines, including veterinary medicine, pediatric oncology, social work, and animal-assisted therapy.

    Pfizer Animal Health
    Pfizer Animal Health, the Pfizer Foundation, and AHA first partnered for this unique study in 2010. The partnership is a part of Pfizer Animal Health’s Commitment to Veterinarians™ platform—which offers support through training and education, research and development, investing in the future of the veterinary profession, and philanthropy.  Pfizer Animal Health underscored its commitment to this particular research with a grant to AHA in 2011. To learn more visit http://www.PfizerAnimalHealth.com.

    American Humane Association
    As the nation’s voice for the protection of children and animals, American Humane Association reaches millions of people every day through groundbreaking research, education, training, and services that span a wide network of organizations, agencies, and businesses. For more information, visit American Humane Association at www.americanhumane.org.

    Source: Pfizer Animal Health and American Humane Association


    Did you know... In both the US and Europe, approximately 50% of money spent on pets is used on regular visits to veterinarians and preventative measures. Read More

    Stay on top of all our latest content — sign up for the Vetlearn newsletters.
    • More